Effect of IGF-1 on IFN-γR2 expression in human lymphoid cell lines
. | . | . | % of IFN-γR2†in the presence of . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Line . | Lineage . | Serum* . | Medium . | IGF-1‡ . | αIGF-1R§ . | Insulin¶ . | |||
| ST4 | T | + | 26 (18) | 18 (7) | 67 (38) | 25 (19) | |||
| - | 46 (12) | 18 (8) | NE | 41 (25) | |||||
| Jurkat | T | + | 22 (7) | 13 (6) | 41 (12) | 21 (8) | |||
| - | 40 (19) | 22 (9) | NE | 45 (20) | |||||
| Molt-4 | T | + | 29 (23) | 26 (10) | 75 (48) | 32 (29) | |||
| - | 62 (34) | 21 (8) | NE | 56 (34) | |||||
| Raji | B | + | 46 (37) | 48 (53) | 49 (43) | 49 (41) | |||
| - | 44 (39) | 47 (47) | NE | 48 (40) | |||||
| U937 | Myeloid | + | 91 (105) | 93 (140) | 95 (168) | 94 (161) | |||
| - | 90 (132) | 92 (124) | NE | 91 (109) | |||||
. | . | . | % of IFN-γR2†in the presence of . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Line . | Lineage . | Serum* . | Medium . | IGF-1‡ . | αIGF-1R§ . | Insulin¶ . | |||
| ST4 | T | + | 26 (18) | 18 (7) | 67 (38) | 25 (19) | |||
| - | 46 (12) | 18 (8) | NE | 41 (25) | |||||
| Jurkat | T | + | 22 (7) | 13 (6) | 41 (12) | 21 (8) | |||
| - | 40 (19) | 22 (9) | NE | 45 (20) | |||||
| Molt-4 | T | + | 29 (23) | 26 (10) | 75 (48) | 32 (29) | |||
| - | 62 (34) | 21 (8) | NE | 56 (34) | |||||
| Raji | B | + | 46 (37) | 48 (53) | 49 (43) | 49 (41) | |||
| - | 44 (39) | 47 (47) | NE | 48 (40) | |||||
| U937 | Myeloid | + | 91 (105) | 93 (140) | 95 (168) | 94 (161) | |||
| - | 90 (132) | 92 (124) | NE | 91 (109) | |||||
NE indicates not evaluated.
Treated cells were cultured for 24 hours in the presence (+) or absence (-) of 10% FCS.
Percentage of IFN-γR2—positive cells evaluated by flow cytometry using anti—IFN-γR2 mAb. Percentages were calculated by subtracting the positivity of nonspecific fluorescence given by isotype-matched control lg and are from 1 of 3 independently performed representative experiments. Mean fluorescence intensity (MFI) is in parentheses.
100 ng/mL.
10 μg/mL.
3600 ng/mL.